Early rheumatoid arthritis in a patient with Sjögren's syndrome and pulmonary nodular amyloidosis: clinical implication of early limited use of infliximab

References

• van der Heijide D. Joint erosions and patients with early rheuma-toid arthritis. Br J Ftheumatol 1995;34 Suppl 2:74–8.
   Google Scholar
• Nell VP, Machold KP, Ebert G, Stamm TA, Uffmann M, Smolen JS. Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheu-matoid arthritis. Ftheumatology (Oxford) 2004;43:906–14.
   PubMed Web of Science ®Google Scholar
• Pavy S, Constantin A, Pham T, Gossec L, Maillefert JF, Cantagrel A, et al. Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006;73:388–95.
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheuma-toid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594–602.
   Google Scholar
• St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004;50:3432–43.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261–5.
   Google Scholar
• Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005;41 Suppl 3:S194–8.
   Google Scholar
• Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Ftheumatol 2006;2: 602–10.
   PubMedGoogle Scholar
• Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy 2005;25:1181–92.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis com-pared with controls: a population-based study. Arthritis Rheum 2002;46:2287–93.
   Google Scholar
• Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexan-der EL, Carsons SE, et al. Classification criteria for Sjogren's syn-drome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554–8.
   Google Scholar
• Buch MH, Marzo-Ortega H, Bingham SJ, Emery P. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals. Ftheumatology (Oxford) 2004;43:243–4.
   PubMed Web of Science ®Google Scholar
• Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a 12-month-randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52: 27–35.
   Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, con-trolled trial. Arthritis Rheum 2005;52:3381–90.
   Google Scholar
• Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007;146:406–15.
   Google Scholar
• van der Kooij SM, van der Biji AE, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Gerards AH, et al. Remis-sion induction in early rheumatoid arthritis (RA) with initial inflixima (IFX) and methotrexate (MTX) therapy: the disease course after IFX discontinuation in the BeSt trial. Arthritis Rheum 2006;54 Suppl:5302.
   Google Scholar
• Yamada T, Nakajima A, Inoue E, Tanaka E, Hara M, Tomatsu T, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan. Ann Rheum Dis 2006;65:1661–3.
   PubMed Web of Science ®Google Scholar
• Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma develop- ment: 26 cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46: 3151–8.
   Google Scholar
• Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2757–64.
   PubMed Web of Science ®Google Scholar
• Baecklund E, Ekbom A, Sparen P, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheu-matoid arthritis: nested case-control study. BMJ 1998;317:180–1.
   Google Scholar
• Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syn-drome. Ann Intern Med 1978;89:888–92.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702–10.
   PubMed Web of Science ®Google Scholar
• Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis. The Mayo Clinic experience from 1980 to 1993. Ann Intern Med 1996;124: 407–13.
   Google Scholar
• Sipe JD. Amyloidosis. Crit Rev Clin Lab Sci 1994;31:325–54.
   PubMed Web of Science ®Google Scholar
• Gillmore JD, Hawkins PN. Amyloidosis and the respiratory tract. Thorax 1999;54:444–51.
   PubMed Web of Science ®Google Scholar
• Westermark P, Benson MD, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, et al. Amyloid fibril protein nomenclature-2002. Amyloid 2002;9:197–200.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Kobayashi T, Makiyama M, Kitada S, Fujishima M, Hagari Y, et al. Monodonality of infiltrating plasma cells in primary pulmonary nodular amyloidosis: detection with polymerase chain reaction. J Clin Pathol 1999;52:464–7.
   PubMed Web of Science ®Google Scholar
• Hagari Y, Mihara M, Konohana I, Ueki H, Yamamoto 0, Koizumi H. Nodular localized cutaneous amyloidosis: further demonstra-tion of monoclonality of infiltrating plasma cells in four additional Japanese patients. Br J Dermatol 1998;138: 652–4.
   Google Scholar
• Laeng RH, Altermatt HJ, Scheithauer BW, Zimmermann DR. Amyloidomas of the nervous system: a monoclonal B-cell disorder with monotypic amyloid light chain lambda amyloid production. Cancer 1998;82:362–74.
   PubMed Web of Science ®Google Scholar
• Quismorio FP Jr. Pulmonary involvement in primary Sjogren's syndrome. Curr Opin Pulm Med 1996;2:424–8.
   Google Scholar
• Kobayashi H, Matsuoka R, Kitamura S, Tsunoda N, Saito K. Sj8gren's syndrome with multiple bullae and pulmonary nodular amyloidosis. Chest 1988;94: 438–40.
   Google Scholar
• Jeong YJ, Lee KS, Chung MP, Han J, Chung MJ, Kim KI, et al. Amyloidosis and lymphoproliferative disease in Sjögren's syn-drome: thin-section computed tomography findings and histopath-ologic comparisons. J Comput Assist Tomogr 2004;28:776–81.
   PubMed Web of Science ®Google Scholar